The Future of TCR-like Antibodies in Diagnosis and Potential Application Targets
Current Molecular Medicine · 2025
DOI: 10.2174/0115665240297179240514030532 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Molecular Medicine, 2025. Verfasst von Huaqiang Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Research in Molecular Medicine, Universiti Sains Malaysia, Penang, 11800, Minden, Malaysia. Hauptthemen laut MEDLINE: Receptors, Antigen, T-Cell, Neoplasms, Antibodies. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 109 Literaturangaben. Gefördert von: Ministry of Higher Education Malaysia for Higher Institution Centre of Excellence, Ministry of Higher Education Malaysia for Fundamental Research Grant Scheme.
Abstract (Originalsprache)
The human leukocyte antigen (HLA, also known as the major histocompatibility complex or MHC) system, is responsible for immune monitoring of the intracellular proteome of all nucleated cells. The presentation of antigen peptides separates malignant or infected cells from their healthy counterparts and forms aberrant cells tagged as the foundation for identification. Therefore, peptide-MHC molecules can give potential diagnostic targets for cancer or infection. TCR-like antibodies recognize specific peptides that bind to MHC molecules, allowing them to target Such inaccessible cytoplasmic or nuclear tumors or virus-associated antigens. It binds to MHC, presenting peptides found on the surface of target cells. These antibodies have shown promising clinical applications in diagnosing and imaging cancer and infected cells. This review presents the current situation of TCR-like antibodies and its prospects for application in the field of intracellular antigen diagnostics. It also lists the potential application targets of TCR, like antibodies in various disease diagnoses, providing valuable information for developing diagnostic reagents and selecting targets in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Research in Molecular Medicine, Universiti Sains Malaysia, Penang, 11800, Minden, Malaysia.
- Faculty of Medicine, Centre for Tissue Engineering and Regenerative Medicine (CTERM), Universiti Kebangsaan Malaysia, Kuala Lumper, Malaysia.
Förderung
- Ministry of Higher Education Malaysia for Higher Institution Centre of Excellence
- Ministry of Higher Education Malaysia for Fundamental Research Grant Scheme
Zitieren
APA
Liu, H., Dass, S. A., Balakrishnan, V., Nordin, F., & Tye, G. J. (2025). The Future of TCR-like Antibodies in Diagnosis and Potential Application Targets. Current Molecular Medicine. https://doi.org/10.2174/0115665240297179240514030532
Vancouver
Liu H, Dass SA, Balakrishnan V, Nordin F, Tye GJ. The Future of TCR-like Antibodies in Diagnosis and Potential Application Targets. Current Molecular Medicine. 2025. doi:10.2174/0115665240297179240514030532
BibTeX
@article{Liu2025,
author = {Liu, Huaqiang and Dass, Sylvia Annabel and Balakrishnan, Venugopal and Nordin, Fazlina and Tye, Gee Jun},
title = {The Future of TCR-like Antibodies in Diagnosis and Potential Application Targets},
journal = {Current Molecular Medicine},
year = {2025},
doi = {10.2174/0115665240297179240514030532}
}
EUVIMED